Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
AssigneeRoche Diagnostics Operations, Inc.
InventorsMartin Klammer, Johanna Carolina Sillman, Anika Mang, Martin Hund, Annunziata Di Domenico, Deirdre Mary Allegranza
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.
Claims22
A method of assessing whether a patient has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, said method comprising:
- (a) determining the amount or concentration of LTA4H in a sample of the patient;
- and
- (b) comparing the determined amount or concentration to a reference.
A method of selecting a patient for therapy of PCOS, said method comprising:
- (a) determining the amount or concentration of LTA4H in a sample of the patient;
- and
- (b) comparing the determined amount or concentration to a reference.
A method for monitoring PCOS progression in a patient having PCOS or for monitoring response to treatment in a patient having PCOS, said method comprising:
- (a) determining the level of LTA4H in a first sample of the patient;
- (b) determining the level of LTA4H in a second sample of the patient which has been obtained after the first sample;
- (c) comparing the level of LTA4H in the first sample to the level of LTA4H in the second sample;
- and
- (d) monitoring progression in the patient suffering from PCOS or being treated for PCOS, based on the results of step c).
(canceled)
(canceled)
Dependencies are inferred from the claim text.